"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 1 | 1 | 2 |
| 2001 | 4 | 0 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 4 | 6 |
| 2008 | 6 | 5 | 11 |
| 2009 | 2 | 4 | 6 |
| 2010 | 4 | 0 | 4 |
| 2011 | 4 | 2 | 6 |
| 2012 | 5 | 2 | 7 |
| 2013 | 4 | 3 | 7 |
| 2014 | 5 | 4 | 9 |
| 2015 | 6 | 8 | 14 |
| 2016 | 4 | 6 | 10 |
| 2017 | 4 | 4 | 8 |
| 2018 | 5 | 8 | 13 |
| 2019 | 4 | 7 | 11 |
| 2020 | 3 | 3 | 6 |
| 2021 | 5 | 5 | 10 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 5 | 5 | 10 |
| 2025 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).
-
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. Oncologist. 2025 Jul 04; 30(7).
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2025 May 01; 31(9):1667-1675.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e600-e606.
-
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb; 21(3):303-311.
-
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 Dec 06; 29(12):1032-1043.